Urology Clinical Trials: Metastatic Urothelial Cancer (Upper Tract and Bladder)

- **1st Line**: Chemo vs Immunotherapy
  - VICC URO 1724: A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma
  - VICC URO 16158: A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (ANTI-PD-L1 Antibody) as Monotherapy and in Combination with Platinum-Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma

- **2nd Line and Above Targeted**: Relapsed/Refractory after 1 platinum-containing regimen for metastatic or inoperable disease
  - VICC URO 1722: An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract whose Tumors Harbor a TSC1 or a TSC2 Mutation
  - VICC URO 1668: A Phase I/II Study Exploring the Safety, Tolerability, and Efficacy of INCAGNO1949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

- **2nd Line and Above Non-Targeted**: TSC1 TSC2
  - VICC PHI 1394: A Phase 1/II Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

- **Trial Pending**
  - VICC URO P1777: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGNO1949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

**KEY**
- accrual on hold
- open

Check the Phase 1 flowchart for additional clinical trials
Check the Molecular Multi-disease flowchart
Check the Advanced Solid Tumors Multi-Disease flowchart

Team Leader Signature and Date: ________________________________